Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Iovance Biotherapeutics Inc Stock Research

IOVA

5.04USD-0.21(-4.00%)Delayedas of 21 Sep 2023, 03:08 pm
Watchlist

Market Summary

USD5.04-0.21
Delayedas of 21 Sep 2023, 03:08 pm
-4.00%

IOVA Alerts

  • 2 major insider buys recently.

IOVA Stock Price

IOVA RSI Chart

IOVA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-2.82

Price/Sales (Trailing)

1.2K

EV/EBITDA

-2.28

Price/Free Cashflow

-3.33

IOVA Price/Sales (Trailing)

IOVA Profitability

Return on Equity

-61.73%

Return on Assets

-49.91%

Free Cashflow Yield

-30.07%

IOVA Fundamentals

IOVA Revenue

Revenue (TTM)

952.0K

IOVA Earnings

Earnings (TTM)

-418.8M

Earnings Y/Y

-7.23%

Earnings Q/Q

0.78%

Price Action

52 Week Range

4.4110.41
(Low)(High)

Last 7 days

-3.4%

Last 30 days

-16.5%

Last 90 days

-35.3%

Trailing 12 Months

-50.9%

IOVA Financial Health

Current Ratio

7.31

IOVA Investor Care

Shares Dilution (1Y)

42.86%

Diluted EPS (TTM)

-2.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for IOVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-18
MCPEAK MERRILL A
bought
55,600
5.56
10,000
-
2023-09-15
Rothbaum Wayne P.
bought
26,500,000
5.3
5,000,000
-
2023-07-14
GRAF FINCKENSTEIN FRIEDRICH
sold (taxes)
-10,825
7.76
-1,395
chief medical officer
2023-07-14
Vogt Frederick G
sold (taxes)
-68,683
7.76
-8,851
interim ceo & general counsel
2023-07-14
GRAF FINCKENSTEIN FRIEDRICH
acquired
-
-
2,813
chief medical officer
2023-07-14
Vogt Frederick G
acquired
-
-
20,834
interim ceo & general counsel
2023-07-14
BILINSKY IGOR
sold (taxes)
-10,825
7.76
-1,395
chief operating officer
2023-07-14
BILINSKY IGOR
acquired
-
-
2,813
chief operating officer
2023-04-14
BILINSKY IGOR
sold (taxes)
-7,867
5.64
-1,395
chief operating officer
2023-04-14
GRAF FINCKENSTEIN FRIEDRICH
sold (taxes)
-7,867
5.64
-1,395
chief medical officer

1–10 of 50

Which funds bought or sold IOVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
34.00
260
-%
2023-08-24
PERCEPTIVE ADVISORS LLC
reduced
-8.5
5,090,550
98,816,300
2.86%
2023-08-23
WOLVERINE TRADING, LLC
added
70.7
195,164
399,164
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
sold off
-100
-68,432
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
0.61
16,500
119,480
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
47.18
680,504
1,658,430
-%
2023-08-16
GTS SECURITIES LLC
new
-
440,162
440,162
0.01%
2023-08-16
Nuveen Asset Management, LLC
added
3.42
2,524,140
15,694,100
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
52.46
1,146,140
2,660,910
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
added
3.33
4,000
24,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying IOVA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IOVA
No. of Funds

Schedule 13G FIlings of Iovance Biotherapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 17, 2023
point72 asset management, l.p.
4.6%
7,347,600
SC 13G
Feb 14, 2023
avoro capital advisors llc
4.4%
7,020,000
SC 13G/A
Feb 14, 2023
perceptive advisors llc
6.3%
9,971,780
SC 13G/A
Feb 09, 2023
vanguard group inc
9.16%
14,463,082
SC 13G/A
Feb 06, 2023
wellington management group llp
0.27%
421,610
SC 13G/A
Feb 03, 2023
blackrock inc.
7.7%
12,076,276
SC 13G
Feb 02, 2023
state street corp
9.32%
14,715,475
SC 13G
Jan 13, 2023
quogue capital llc
12.52%
2e+07
SC 13D/A
Dec 30, 2022
mhr fund management llc
5.8%
10,511,920
SC 13G
Feb 24, 2022
blackrock inc.
4.7%
7,408,505
SC 13G/A

Recent SEC filings of Iovance Biotherapeutics

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 15, 2023
4
Insider Trading
Sep 15, 2023
8-K
Current Report
Aug 18, 2023
8-K
Current Report
Aug 08, 2023
10-Q
Quarterly Report
Aug 08, 2023
8-K
Current Report
Jul 17, 2023
4
Insider Trading
Jul 17, 2023
4
Insider Trading
Jul 17, 2023
4
Insider Trading
Jul 13, 2023
8-K
Current Report

Peers (Alternatives to Iovance Biotherapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
145.2B
26.6B
4.13% 21.09%
18.2
5.46
0.75% 21.34%
94.5B
27.4B
-0.16% 19.51%
17.24
3.45
-0.48% 32.56%
39.4B
10.7B
-6.80% -20.18%
32.68
3.7
-53.67% -91.41%
37.7B
10.0B
-1.71% 27.59%
14.15
3.78
-6.23% 29.40%
MID-CAP
11.2B
1.7B
5.59% 6.81%
63.29
6.67
29.01% 1345.90%
4.5B
-
-3.04% 140.92%
-7.66
48.33
54.84% -12.96%
3.1B
-
-4.51% -22.98%
-23.78
37.44
122.90% 54.78%
2.0B
80.2M
6.46% -52.82%
-6.01
24.54
42.17% -39.82%
SMALL-CAP
1.5B
121.2M
4.38% -25.42%
-5.13
12.17
-70.36% -531.73%
1.2B
952.0K
-16.53% -50.89%
-2.82
1.2K
- -11.27%
980.2M
15.3M
-15.63% 3.04%
-5.4
64.02
1090.59% -36.57%
664.9M
1.6B
-12.64% -74.33%
-1.13
0.42
23.74% 60.24%
112.7M
2.1M
-6.14% -67.90%
-1.12
54.83
487.70% -8.66%
8.7M
2.2M
58.19% 783.63%
-2.08
4.04
45.07% 43.77%
4.1M
-
-12.28% -96.10%
-0.05
3.21
- -129.46%

Iovance Biotherapeutics News

MarketBeat
SG Americas Securities LLC Takes $2.59 Million Position in Iovance ....
MarketBeat,
10 hours ago
Investing.com UK

Returns for IOVA

Cumulative Returns on IOVA

0.5%


10-Year Cumulative Returns

-6.3%


7-Year Cumulative Returns

-17.3%


5-Year Cumulative Returns

-47.4%


3-Year Cumulative Returns

Risks for IOVA

What is the probability of a big loss on IOVA?

100%


Probability that Iovance Biotherapeutics stock will be more than 20% underwater in next one year

90.8%


Probability that Iovance Biotherapeutics stock will be more than 30% underwater in next one year.

88.1%


Probability that Iovance Biotherapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IOVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Iovance Biotherapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Iovance Biotherapeutics

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q2
Revenue-1.00
  S&GA Expenses-104
  R&D Expenses-322
Earnings Before Taxes--428
Net Income--418
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-8.2%757825664546611701777829853751768782818288345396436462481271285
  Current Assets-56.9%275638479370432490508583667605636724783256316367411445475266280
    Cash Equivalents-57.7%23054423211810892.0084.0059.0083.0013267.0068.0016153.0019.0039.0077.0054.0082.0081.00246
  Inventory-10.00--------------------
  Net PPE2.4%11311010510110110310188.0080.0073.0059.0039.0019.0014.009.006.004.004.003.003.003.00
Liabilities13.2%17915816415213814915613010810311270.0059.0045.0046.0041.0039.0027.0015.00--
  Current Liabilities1.6%89.0087.0091.0079.0064.0077.0089.0065.0061.0055.0055.0064.0055.0040.0039.0035.0034.0022.0014.0017.0014.00
Shareholder's Equity-13.2%579667500394473552622698744647656712758243299355397435466254271
  Retained Earnings-6.4%-1,782-1,675-1,568-1,463-1,363-1,264-1,172-1,073-986-905-830-761-703-640-570-507-457-4100.00-340-306
  Additional Paid-In Capital0.8%2,3602,3432,0691,8591,8391,8181,7951,7711,7311,5531,4871,4731,4618838690.000.00845839594577
Shares Outstanding0.1%22522418815815715715715615414914814714612712612612412312397.0093.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-5.1%-335-318-292-268-262-239-227-236-219-202-205-196-197-195-158-136-122-112-101-90.66-84.18
  Share Based Compensation-7.4%72.0077.0084.0084.0083.0075.0070.0061.0052.0048.0041.0036.0032.0028.0024.0024.0023.0022.0020.0017.0015.00
Cashflow From Investing-78.1%71.003232563252649.000.00-10.45-76.16-340-317-349-29318990.00-143-296-385-386-179-15.98
Cashflow From Financing0.7%4504471904.0024.0019023923821862357657657510.006.00243255255424188232

IOVA Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Condensed Consolidated Statements of Operations    
Total revenue$ 238 $ 238 
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Product [Member]Product [Member]Product [Member]Product [Member]
Costs and expenses    
Cost of sales$ 2,050 $ 2,050 
Research and development86,347$ 73,406169,081$ 141,706
Selling, general and administrative21,92726,32850,04949,741
Total costs and expenses110,32499,734221,180191,447
Loss from operations(110,086)(99,734)(220,942)(191,447)
Other income    
Interest income, net3,0813856,567491
Net Loss before income taxes(107,005)(99,349)(214,375)(190,956)
Income tax benefit477 477 
Net Loss$ (106,528)$ (99,349)$ (213,898)$ (190,956)
Net Loss Per Share of Common Stock, Basic$ (0.47)$ (0.63)$ (0.98)$ (1.21)
Net Loss Per Share of Common Stock, Diluted$ (0.47)$ (0.63)$ (0.98)$ (1.21)
Weighted Average Shares of Common Stock Outstanding, Basic224,481157,274219,117157,194
Weighted Average Shares of Common Stock Outstanding, Diluted224,481157,274219,117157,194

IOVA Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 230,010$ 231,731
Trade accounts receivable33 
Short-term investments20,884240,114
Inventory9,720 
Prepaid expenses and other assets14,2317,271
Total Current Assets274,878479,116
Property and equipment, net112,549105,232
Intangible assets, net235,511 
Operating lease right-of-use assets67,63173,015
Restricted cash66,4306,430
Long-term assets294189
Total Assets757,293663,982
Current Liabilities  
Accounts payable31,15726,603
Accrued expenses46,62052,295
Operating lease liabilities10,86612,587
Total Current Liabilities88,64391,485
Non-Current Liabilities  
Operating lease liabilities - non-current68,84471,859
Deferred tax liabilities20,237 
Long-term note payable1,0001,000
Total Non-Current Liabilities90,08172,859
Total Liabilities178,724164,344
Commitments and contingencies
Stockholders' Equity  
Common stock, $0.000041666 par value; 500,000,000 shares authorized, 224,688,434 and 187,812,072 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively98
Accumulated other comprehensive income (loss)325(902)
Additional paid-in capital2,360,4682,068,867
Accumulated deficit(1,782,236)(1,568,338)
Total Stockholders' Equity578,569499,638
Total Liabilities and Stockholders' Equity757,293663,982
Series A Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value00
Series B Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value$ 3$ 3
Frederick G. Vogt
320
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.